AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvar Cancer
Conditions
Vulvar Cancer
Trial Timeline
Aug 25, 2023 → Dec 15, 2025
NCT ID
NCT05932212About AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin
AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin is a phase 2 stage product being developed by Akeso for Vulvar Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05932212. Target conditions include Vulvar Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Vulvar Cancer were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05932212 | Phase 2 | Recruiting |
Competing Products
7 competing products in Vulvar Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 35 |
| Estradiol | Sun Pharmaceutical | Phase 3 | 32 |
| Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark) | Glenmark Pharmaceuticals | Phase 3 | 40 |
| Cisplatin + Pembrolizumab | Merck | Phase 2 | 39 |
| Cardunolizumab | Innovent Biologics | Phase 2 | 42 |
| AVA6103 | Avacta Group | Phase 1 | 26 |
| VGX-3100 + Imiquimod 5% Cream | Inovio Pharmaceuticals | Phase 2 | 25 |